The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-α in human breast tumors in vivo

Breast Cancer Research

Volumn 16, Issue 3, 2014, Pages

  Shrivastav, Anuraag ^a,b   Bruce, Mary C ^a   Jaksic, Danira ^b   Bader, Tarek ^a   Seekallu, Srinivas ^a   Penner, Carla ^a   Nugent, Zoann ^a   Watson, Peter ^a,c   Murphy, Leigh ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF WINNIPEG   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN; ESTROGEN RECEPTOR ALPHA, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; S6 KINASE; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BREAST CANCER; BREAST TUMOR; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MICROSCOPY; OVERALL SURVIVAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING ASSAY; RECURRENCE FREE SURVIVAL; TISSUE MICROARRAY; TREATMENT RESPONSE; WESTERN BLOTTING; BIOSYNTHESIS; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; DRUG RESISTANCE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PHOSPHORYLATION; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MCF-7 CELLS; MIDDLE AGED; MULTIPROTEIN COMPLEXES; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TAMOXIFEN; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84902277694     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3660     Document Type: Article

References (45)

1. Ali S, Coombes R. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Rev 2002, 2:101-112.
2. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643. 10.1038/nrc2713, 19701242.
3. Le Romancer M, Poulard C, Cohen P, Sentis S, Renoir JM, Corbo L. Cracking the estrogen receptor's posttranslational code in breast tumors. Endocr Rev 2011, 32:597-622. 10.1210/er.2010-0016, 21680538.
4. Murphy LC, Seekallu SV, Watson PH. Clinical significance of estrogen receptor phosphorylation. Endocr Relat Cancer 2011, 18:R1-R14. 10.1677/ERC-10-0070, 21149515.
5. Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Troup S, Begic S, Parisien M, Watson PH, Murphy LC. Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor alpha (ERalpha) in tissue microarrays of ERalpha positive human breast carcinomas. Breast Cancer Res Treat 2009, 118:443-453. 10.1007/s10549-008-0267-z, 3448371, 19104930.
6. Skliris GP, Nugent ZJ, Rowan BG, Penner CR, Watson PH, Murphy LC. A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer. Endocr Relat Cancer 2010, 17:589-597. 10.1677/ERC-10-0030, 20418363.
7. Skliris GP, Nugent ZJ, Watson PH, Murphy LC. Estrogen receptor alpha phosphorylated at tyrosine 537 is associated with poor clinical outcome in breast cancer patients treated with tamoxifen. Horm Cancer 2010, 1:215-221. 10.1007/s12672-010-0049-z, 21761367.
8. Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res 2010, 70:8852-8862. 10.1158/0008-5472.CAN-10-1039, 20959472.
9. Finetti P, Cervera N, Charafe-Jauffret E, Chabannon C, Charpin C, Chaffanet M, Jacquemier J, Viens P, Birnbaum D, Bertucci F. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res 2008, 68:767-776. 10.1158/0008-5472.CAN-07-5516, 18245477.
10. Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, Yang D, Zhang W, Shifa BA, Photiou A, Tralau-Stewart C, Castellano L, Green AR, Coombes RC, Ellis IO, Ali S, Lenz HJ, Stebbing J. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med 2011, 17:715-719. 10.1038/nm.2351, 21602804.
11. O'Regan R, Hawk NN. mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. Expert Opin Ther Targets 2011, 15:859-872. 10.1517/14728222.2011.575362, 21476875.
12. Beeram M, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann Oncol 2007, 18:1323-1328. 10.1093/annonc/mdm170, 17693645.
13. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005, 11:5319-5328. 10.1158/1078-0432.CCR-04-2402, 16033851.
14. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem 2009, 284:6361-6369. 10.1074/jbc.M807532200, 19112174.
15. Snell L, Watson P. Breast tissue banking: collection, handling, storage, and release of tissue for breast cancer research. Methods Mol Med 2006, 120:3-24.
16. Watson P, Snell L, Parisien M. The NCIC-Manitoba Breast Tumor Bank: a resource for applied cancer research. CMAJ 1996, 155:281-283. 1487994, 8705906.
17. CTRNet. [http://www.CTRNet.ca].
18. Skliris G, Leygue E, Curtis-Snell L, Watson P, Murphy L. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 2006, 95:616-626. 10.1038/sj.bjc.6603295, 2360679, 16880783.
19. Weitsman G, Li L, Skliris G, Davie J, Ung K, Curtis-Snell L, Tomes L, Watson P, Murphy L. Estrogen receptor-alpha phosphorylated at Serine 118 is present at the promoters of estrogen-regulated genes and is not altered due to Her2 over-expression. Cancer Res 2006, 66:10162-10170. 10.1158/0008-5472.CAN-05-4111, 17047081.
20. Walsh S, Flanagan L, Quinn C, Evoy D, McDermott EW, Pierce A, Duffy MJ. mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors. Breast 2012, 21:178-182. 10.1016/j.breast.2011.09.008, 21963359.
21. Copp J, Manning G, Hunter T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 2009, 69:1821-1827. 10.1158/0008-5472.CAN-08-3014, 2652681, 19244117.
22. Rosner M, Schipany K, Hengstschläger M. p70 S6K1 nuclear localization depends on its mTOR-mediated phosphorylation at T389, but not on its kinase activity towards S6. Amino Acids 2012, 42:2251-2256. 10.1007/s00726-011-0965-4, 21710263.
23. Yin XJ, Wang G, Khan-Dawood FS. Requirements of phosphatidylinositol-3 kinase and mammalian target of rapamycin for estrogen-induced proliferation in uterine leiomyoma- and myometrium-derived cell lines. Am J Obstet Gynecol 2007, 196:176.
24. Kazi AA, Molitoris KH, Koos RD. Estrogen rapidly activates the PI3K/AKT pathway and hypoxia-inducible factor 1 and induces vascular endothelial growth factor A expression in luminal epithelial cells of the rat uterus. Biol Reprod 2009, 81:378-387. 2849827, 19420388.
25. Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, Berruti A. Down-regulation of phosphatidylinositol 3′-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clin Cancer Res 2008, 14:2673-2680. 10.1158/1078-0432.CCR-07-1046, 18451231.
26. Yu J, Thomson TC, Johnson J. Cross talk between estradiol and mTOR kinase in the regulation of ovarian granulosa proliferation. Reprod Sci 2012, 19:143-151. 10.1177/1933719111424447, 22383759.
27. Yu J, Henske EP. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain. Cancer Res 2006, 66:9461-9466. 10.1158/0008-5472.CAN-06-1895, 17018601.
28. Shrivastav A, Murphy L. Interactions of PI3K/Akt/mTOR and estrogen receptor signaling in breast cancer. Breast Cancer Manage 2012, 1:235-249.
29. Bakarakos P, Theohari I, Nomikos A, Mylona E, Papadimitriou C, Dimopoulos AM, Nakopoulou L. Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas. Histopathology 2010, 56:876-882. 10.1111/j.1365-2559.2010.03570.x, 20636791.
30. Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 2006, 19:238-245. 10.1038/modpathol.3800525, 16341149.
31. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004, 10:6779-6788. 10.1158/1078-0432.CCR-04-0112, 15501954.
32. Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskjold B, Stal O. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Res Treat 2013, 137:397-406. 10.1007/s10549-012-2376-y, 3539073, 23242584.
33. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, Gustafsson JA. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007, 87:905-931. 10.1152/physrev.00026.2006, 17615392.
34. Osborne C, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 2005, 23:1616-1622. 10.1200/JCO.2005.10.036, 15755967.
35. Schiff R, Massarweh S, Shou J, Bharwani L, Mohsin S, Osborne C. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004, 10:331S-336S. 10.1158/1078-0432.CCR-031212, 14734488.
36. Phosphonet. [http://www.phosphonet.ca].
37. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945. 10.1101/gad.1212704, 15314020.
38. Lippman M, Bolan G. Oestrogen responsive human breast cancer in long term tissue culture. Nature 1975, 256:592-593. 10.1038/256592a0, 170527.
39. Lippman M, Bolan G, Huff K. Effects of estrogens and antiestrogens on hormone-responisve human breast cancer in long-term tissue culture. Cancer Res 1976, 36:4595-4601.
40. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012, 481:389-393. 3272464, 22217937.
41. Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A'Hern R, Nerurkar A, Osin P, Smith IE, Dowsett M. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 2010, 12:R76. 10.1186/bcr2719, 3096968, 20920193.
42. Neumeister VM, Anagnostou V, Siddiqui S, England AM, Zarrella ER, Vassilakopoulou M, Parisi F, Kluger Y, Hicks DG, Rimm DL. Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst 2012, 104:1815-1824. 10.1093/jnci/djs438, 3514166, 23090068.
43. Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, Deng J, VanMeter AJ, Geho DH, Pastore L, Sennesh J, Petricoin EF, Liotta LA. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 2008, 7:1998-2018. 10.1074/mcp.M700596-MCP200, 2559936, 18667411.
44. Hiller T, Snell L, Watson P. Microdissection/RT-PCR analysis of gene expression. Biotechniques 1996, 21:38-44.
45. Barnes RO, Parisien M, Murphy LC, Watson PH. Influence of evolution in tumor biobanking on the interpretation of translational research. Cancer Epidemiol Biomarkers Prev 2008, 17:3344-3350. 10.1158/1055-9965.EPI-08-0622, 19064549.